Salute e Benessere
Colorectal Cancer Market Set to Expand Throughout Forecast Period (2025-2034) Driven by Increasing Screening Rates and Novel Drug Approvals | DelveInsight
Discover the colorectal cancer new treatment @
The growing global incidence of colorectal cancer is a primary market driver, attributed to aging populations, lifestyle changes, and rising risk factors such as obesity, sedentary habits, diets high in processed meats, smoking, and alcohol consumption.
The increased use of molecular profiling (MSI-H, BRAF V600E, HER2, and KRAS G12C) enables more personalized and effective treatment strategies.
Emerging targets such as provide new opportunities for drug development.
Several colorectal cancer therapies are currently being evaluated in clinical trials, including and others.
The treatment strategy may involve a combination of surgery, radiation therapy, immunotherapy, and chemotherapy, each aimed at slowing disease progression and, in many cases, temporarily reducing the size of a cancerous tumor. Palliative care also plays a crucial role in alleviating symptoms and managing side effects associated with treatment.
In first-line palliative chemotherapy, either alone or in combination with targeted therapies, the foundation typically includes a fluoropyrimidine (FP), such as intravenous 5-fluorouracil (5-FU) or its oral counterpart, capecitabine, used in various combinations and dosing schedules. Among these, oral capecitabine serves as an alternative to intravenous . Studies have shown that combination regimens, such as (5-FU/LV/oxaliplatin) and (5-FU/LV/irinotecan), yield higher response rates, improved progression-free survival (PFS), and better overall outcomes compared to 5-FU/LV alone. For patients who no longer respond to FOLFOX or CAPEOX, second-line therapy typically involves irinotecan-based treatments, such as irinotecan monotherapy or FOLFIRI. Evidence suggests that FOLFIRI offers a superior therapeutic index in this setting, with notable safety benefits over irinotecan monotherapy.
Additionally, emerging pipeline candidates, including , are expected to expand treatment options across multiple lines of therapy.
To know more about colorectal cancer treatment options, visit @
Some of the colorectal cancer drugs in clinical trials include (Shanghai Henlius Biotech), (Agenus), (Tizona Therapeutics), (Surgimab), (Novartis), (Bexion Pharmaceuticals), (Syndax Pharmaceuticals), (Exelixis), (AbbVie), (Tyligand Pharmaceuticals), (Bristol Myers Squibb), (Eisai), (Bold Therapeutics), and others.
is a novel humanized recombinant monoclonal antibody (mAb) targeting Programmed Cell Death Protein 1 (PD-1), developed independently by Henlius. It shows promise for the treatment of multiple solid tumors, demonstrating improved pharmacokinetic and pharmacodynamic profiles, along with favorable safety, tolerability, and antitumor activity in preclinical and early-stage clinical studies.
is an investigational, Fc-enhanced human antibody targeting CTLA-4, designed to amplify both innate and adaptive antitumor immune responses. Its innovative design harnesses multiple mechanisms of action to broaden the benefits of immunotherapy, particularly for "cold" tumors that are typically unresponsive or resistant to existing PD-1/CTLA-4 treatments and other investigational agents.
, a first-in-class monoclonal antibody, targets HLA-G, a key immune-suppressive protein in the tumor microenvironment. By blocking HLA-G, TTX-080 aims to restore and enhance immune activity against cancer cells, particularly when used in conjunction with complementary therapeutic approaches.
The anticipated launch of these emerging therapies are poised to transform the colorectal cancer market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the colorectal cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about therapy for colorectal cancer @
Colorectal cancer (CRC) is a malignancy that develops in the colon (large intestine) or rectum and ranks among the most prevalent cancers globally. It typically starts as a small growth, or polyp, on the inner lining of the colon or rectum, which gradually enlarges and becomes cancerous over several years. When CRC spreads, or metastasizes, to other organs such as the liver or lungs, it is referred to as metastatic colorectal cancer (mCRC).
The colorectal cancer epidemiology section provides insights into the historical and current colorectal cancer patient pool and forecasted trends for the leading markets. Among the 7MM countries, as far as age-specific cases are concerned, the accounted for the highest number of cases in 2024.
The colorectal cancer market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:
Download the report to understand which factors are driving colorectal cancer therapeutics market trends @
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CRC companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic colorectal cancer companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic colorectal cancer companies, including among others.
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key microsatellite stable colorectal cancer companies, including , among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo - https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/colorectal-cancer-market-set-to-expand-throughout-forecast-period-20252034-driven-by-increasing-screening-rates-and-novel-drug-approvals--delveinsight-302627755.html